Crizotinib | 1934

A specific, ATP-competitive, small-molecule inhibitor of the receptor tyrosine kinases (RTKs) c-Met and anaplastic lymphoma kinase (ALK). Iinhibits tyrosine phosphorylation of activated ALK at nanomolar concentrations. Inhibits the growth and survival of cell lines dependent upon c-Met or ALK enzymatic activity.

Crizotinib is a specific, ATP-competitive, small-molecule inhibitor of the receptor tyrosine kinases (RTKs) c-Met and anaplastic lymphoma kinase (ALK). Iinhibits tyrosine phosphorylation of activated ALK at nanomolar concentrations. Inhibits the growth and survival of cell lines dependent upon c-Met or ALK enzymatic activity.

1934 | Crizotinib DataSheet

Alternate Name/Synonyms: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine

Appearance: Off-white solid

Formulation: N/A

CAS Number: 877399-52-5

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₁H₂₂Cl₂FN₅O

Molecular Weight: 450.34

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent c-Met and ALK inhibitor

MDL Number: MFCD12407409

PubChem CID: 11626560

SMILES: CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N

InChi: InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1

InChi Key: KTEIFNKAUNYNJU-GFCCVEGCSA-N